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Ruthenium based antimicrobial theranostics –
using nanoscopy to identify therapeutic targets and
resistance mechanisms in Staphylococcus aureus†
Kirsty L. Smitten, *ab Simon D. Fairbanks,a Craig C. Robertson,a Jorge Bernardino de
la Serna, cd Simon J. Foster b and Jim A. Thomas *a
In previous studies we reported that speciﬁc dinuclear RuII complexes are particularly active against
pathogenic Gram-negative bacteria and, unusually for this class of compounds, appeared to display
lowered activity against Gram-positive bacteria. With the aim of identifying resistance mechanisms
speciﬁc to Gram-positive bacteria, the uptake and antimicrobial activity of the lead complex against
Staphylococcus aureus SH1000 and other isolates, including MRSA was investigated. This revealed
diﬀerential, strain speciﬁc, sensitivity to the complex. Exploiting the inherent luminescent properties of
the RuII complex, super-resolution STED nanoscopy was used to image its initial interaction with S.
aureus and conﬁrm its cellular internalization. Membrane damage assays and transmission electron
microscopy conﬁrm that the complex disrupts the bacterial membrane structure before internalization,
which ultimately results in a small amount of DNA damage. A known resistance mechanism against
cationic antimicrobials in Gram-positive bacteria involves increased expression of the mprF gene as this
results in an accumulation of positively charged lysyl-phosphatidylglycerol on the outer leaﬂet of the
cytoplasmic membrane that electrostatically repel cationic species. Consistent with this model, it was
found that an mprF deﬁcient strain was particularly susceptible to treatment with the lead complex. More
detailed co-staining studies also revealed that the complex was more active in S. aureus strains missing,
or with altered, wall teichoic acids.
Introduction
Over the last few decades it has become increasingly clear that
antimicrobial resistance, AMR, is evolving into a global crisis.1–5
Although reports of resistance to antibiotics emerged quite
soon aer their rollout, the current extent and breadth of
resistant infections is unprecedented and continues to rapidly
increase.6–8 Due to a combination of scientic and commercial
reasons, this problem is being exacerbated by a dearth of new
therapeutic leads.9–17 Consequently, in the last few years,
a series of national and international initiatives have been
launched to provide the required economic pull and push to
incentivize new drug discovery programs.2,18 In terms of
chemistry, the need for leads with novel mechanisms of action
to established antibiotics has driven searches into new chem-
ical space.19,20 In this context, the potential of metal complexes
has begun to be revisited.
Even though ground-breaking studies by the Dwyer group in
the mid-twentieth century had established that polypyridyl
complexes of mid-transition metal ions display antimicrobial
activity21 – particularly against Gram-positive organisms22 –
research into metal-based leads stagnated for almost y years.
Now, with the rise in concerns over AMR, interest in such
systems is undergoing a renaissance.23–26
Whilst a number of reports have demonstrated that the
activity of conventional antibiotics can be modulated or
potentiated by connection to metal–organic fragments,27
molecular architectures that are very diﬀerent to natural
systems have also been investigated.28,29 A range of metals have
been used in these studies, but – inspired by Dwyer's early work
– many reports have involved RuII complexes.30–32
In 2011, Aldrich-Wright, Bolhuis and co-workers showed that
mononuclear RuII complexes incorporating the DNA inter-
calating ligand dppz (dppz ¼ dipyridophenazine) display
promising in vivo activity against strains of the Gram-positive
bacterium, Staphylococcus aureus.33 Subsequent reports on
other intercalating34,35 and non-intercalating36 mononuclear
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RuII complexes have revealed comparable activities and such
studies have also been extended to oligonuclear compounds.
Inspired by work from the Kelly group,37,38 Keene and Collins
began investigating dinuclear RuII complexes with exible
linkers as probes for non-canonical DNA structures.39,40
However, on discovering the interesting antibacterial activity of
these systems,41 their work switched focus. A series of studies on
oligonuclear complexes revealed that longer, exible linkers
between metal centres produces higher activity against thera-
peutically resistant Gram-positive pathogens, although activity
against Gram-negative pathogens is still lower.42
The mechanism for the selective therapeutic action of these
compounds has been investigated but is still not fully estab-
lished. Studies indicate that active complexes bind ribosomal
RNA in prokaryotes, but it is also true that they bind RNA in the
eukaryotic nucleus43 A recent combined NMR and computa-
tional study using membrane models suggested that – due to
the increased anionic charge of bacterial membranes – the
complexes selectively bridge bacterial walls, but not eukaryote
membranes.44 Interestingly, these studies also showed that the
bound complexes do not structurally compromise the
membrane as leakage assays revealed no lytic activity.
As part of a program to identify oligonuclear complexes that
recognize biologically relevant ions and biomolecules, the
Thomas group has been investigating the biological properties
of RuII, OsII, and IrIII complexes containing the rigidly planar
poly-aromatic ligand tetrapyridophenazine, tpphz.45–50 Most of
this work has centred on their bio-imaging and therapeutic
potential with eukaryotic cells. But – as our original report on
cell imaging showed that the prototype system, [{Ru(phen)2}2(-
tpphz)]4+, 14+, was readily taken up by S. aureus cells46 – we set
out to develop new dual imaging/antimicrobial theranostics
based on this architecture.
In a recent paper we described the rst results of these
studies, identifying derivatives of 14+, Fig. 1, containing more
lipophilic ancillary ligands that are active against Gram-positive
and Gram-negative bacteria, including members of the multi-
drug resistant ESKAPE group of pathogens.51 Experiments on
the most promising lead suggested that its therapeutic action
was, at least partly, due to disruption of bacterial membrane
structure. Given this distinctive spectrum of activity, we set out
to explore whether 14+ and its analogues are active against the
pathogen S. aureus. Herein, we report the X-ray crystal structure
of the lead system, explore its mechanism of action and identify
resistance mechanisms that explain why it is less active against
Gram-positive bacteria compared to Gram-negative bacteria.
Results and discussion
Crystallographic studies
Crystals grown from rac-44+ suitable for X-ray structure deter-
mination were successfully obtained by vapour diﬀusion of
diethyl ether into a nitromethane solution of its hexauoride
salt. A summary of the crystallographic data and thermal
ellipsoid plots can be found in the ESI.†
As shown in Fig. 2, coordination ligands around the ruthe-
nium centres 44+ dene the expected octahedral geometry,
distorted by accommodation of three chelating ligands. The
resultant Ru–N bond lengths (2.036–2.069 A˚) and bite angles
(79.48–80.84) are consistent with other reported dinuclear
ruthenium polypyridyl complexes, including the closely related
complex [{Ru(bpy)2}2(tpphz)]
4+ (bpy ¼ 202-bipyridine)50,52
Although crystals were grown from rac-44+ – a mixture of the
D,D, L,L and L,L isomers of 44+ – the crystals shows cations
packed in layers of oﬀset coplanar stacks, where each alter-
nating layer is solely comprised of either the D,D or L,L
Fig. 1 Complexes investigated in this study.
Fig. 2 Crystal structure grown from rac-44+. Crystal structure
showing D,D and L,L layers connected by interaction. (A) Space ﬁlling
representation with PF6 counter ions. (B) Stick structure of 4
4+without
counter ions.
Chem. Sci. This journal is © The Royal Society of Chemistry 2019
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enantiomer. Interestingly, when [{Ru(bpy)2}2(tpphz)]
4+ was
similarly crystallized from an unresolved mixture of its stereo-
isomers the resulting structure also only contained the D,D and
L,L forms and it was suggested that L,D form is more soluble
than the enantiomeric pair.52 Alternatively, this phenomenon
may be due to crystal packing eﬀects.
Biological studies
As discussed above, in our recent report, we investigated the
uptake and therapeutic activity of 14+, 34+–54+ against two
examples of the pathogenic ESKAPE group of bacteria; the
EC958 ST131 strain of Gram-negative Escherichia coli and the
V583 strain of Gram-positive Enterococcus faecalis.51 and found
they were more active against the Gram-negative organism.
Further studies showed that the most promising lead, 44+,
appears to be therapeutically active through a number of
mechanisms, which include structural disruption of the Gram-
negative cell membranes.
These intriguing results prompted us to investigate the
therapeutic action of this class of compounds against Gram-
positive bacteria in more detail. For our exemplar of a typical
Gram-positive microorganism we chose S. aureus.
Partially, this choice was prompted by the fact that we had
already established 14+ is readily internalized by S. aureus,46 but
this bacterium also provides an ideal “test-bed” to investigate
potential resistance mechanisms. Apart from the fact that
pathogenic S. aureus strains – particularly methicillin-resistant
variants (MRSA), cause pernicious infections associated with
treatment failure, higher morbidity/mortality rates, and pro-
longed hospitalizations greatly increasing health care costs53–55
– the mechanisms of therapeutic resistance in specic strains
are well studied56–59 and so they can be used to probe the
molecular mechanism of new antimicrobials. Therefore, in this
study we investigate the potency of 14+–54+ against a range of S.
aureus strains. Compounds used in biological studies were the
mixture of stereoisomers, not the crystallised material.
Initially, to identify the most active lead against a represen-
tative wild type strain of S. aureus (SH1000),60 the minimum
inhibitory concentration, MIC, of the complexes in chemically
dened minimal media, CDM, and the commonly used
Mueller-Hinton-II media, MH-II was obtained – Table 1.
Although nutrient-rich growth media, like MH-II, are used as
a standard in clinical assessments of antimicrobials, the
nutrient limited environment provided by CDM also represents
relevant biological conditions during diﬀerent stages of infec-
tion in vivo.61 As with previous studies, the complexes show
increased activity in the CDM, the lower potencies in MH-II
relative to the CDM is likely due to the complexes interacting
with components in the complex media.
Minimum bactericidal concentrations, MBC, were also
calculated for the compounds in minimal media to determined
bactericidal eﬀects – Table 2. As a compound is seen to be
bactericidal if it possesses an MBC that is #4 [MIC],62
a comparison of data indicated that all the tested compounds
are bactericidal.
To conrm that these compounds are bactericidal, cell death
curves were conducted at ve times the MIC concentration for
the two most potent compounds, 44+ and 54+ – see ESI.† A
3Log10 decrease (99.9%) in CFU mL1 is observed, verifying
their bactericidal activity.
Previous research indicated that increasing the lipophilicity
of the compounds increases the activity.41,51 This eﬀect is
apparent here: the most potent compound appears to be the
only true lipophilic compound. However, such direct compari-
sons are misleading, as 54+ precipitated at high concentrations
and 5% DMSO was required to improve its solubility – see ESI†
for growth curves. As 44+ displays comparable potency, but
without addition of DMSO, it was taken as the more promising
lead and investigated in more detail.
In time-kill assays the majority of cells exposed to 44+ die
within 30 min. This is much faster than the oxacillin control,
suggesting that the complex displays a diﬀerent mechanism of
action to this beta-lactam antibiotic. To investigate this rapid
bactericidal eﬀect, ICP-AES-based uptake experiments with
wild-type SH1000 cells exposed to 44+ at time points up to an
hour were carried out – Fig. 3.
In these experiments, measurement of iron content (a trace
element in all cells) was used as a control and, as expected,
a negligible change in [Fe] was observed. CFU/mL readings were
also taken to monitor whether cells were lysing/growing during
the experiment – see ESI.†
Consistent with the rapid cell death observed in the time-kill
assays, accumulation of RuII was also found to be rapid. As
previous work demonstrated that 44+ is taken up into Gram-
negative bacteria through an active transport mechanism,51
uptake by S. aureus was studied in the presence and absence of
glucose over a 60 minute time course and the rates of uptake
were determined (mM min1) for 44+ – see ESI† – at each time
point. In the absence of glucose, accumulation over 5 minutes is
followed by gradual uptake to a nal gure of around 2 1016 g
per cell; assuming an average cell volume63,64 of 1 mm3 this is
equivalent to an intracellular concentration of >1 mM per cell.
Table 1 MIC (mM) results for S. aureus SH1000 in CDM and MH-II
Complex MH-II CDM
14+ 66.7 21.3
24+ 100 64
34+ 50 58.7
44+ 40 4
54+ 20 2
Oxacillin control 2.5 2.5
Table 2 MBC (mM) results for S. aureus SH1000 in CDM and MH-II
Complex MH-II CDM MIC/MBC (CDM)
14+ 114 58.7 2.8
24+ 170 106.7 1.7
34+ 100 85.3 1.5
44+ 80 13.3 3.3
54+ 40 6.7 3.3
Oxacillin control 2.5 2.5 2.5
This journal is © The Royal Society of Chemistry 2019 Chem. Sci.
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Although the uptake prole of the complex in the presence of
glucose displays a similar prole in these conditions there is
signicantly greater intracellular accumulation of ruthenium
(3 mM per cell), suggesting that an energy-dependent active
transport mechanism contributes to the uptake of 44+ into
SH1000 cells. However, in contrast to previously reported
experiments with E. coli,51 ruthenium accumulation within S.
aureus in the absence of glucose does not take place over two
phases, suggesting that the mechanism of uptake for 44+may be
diﬀerent in Gram-negative and Gram-positive bacteria.
Our previous microscopy experiments suggested that the
compound initially binds to lipopolysaccharides on the outer
membrane of E. coli, however S. aureus does not possess an
outer membrane. Therefore, to study the target of 44+ at the
molecular scale, its cellular uptake was monitored by a super
resolution technique, structure illumination microscopy, SIM,
allowing for sub-diﬀraction resolutions of >100 nm (ref. 65 and
66) – Fig. 4.
Within 5 minutes, the majority of cells show that 44+ local-
izes at cell membranes and within the cell cytoplasm. Accu-
mulation of 44+ is uneven, with punctate patterns. By 60
minutes the compound shows distinct foci within cells. The
observation of intracellular accumulation is similar to that for
E. coli when exposed to 44+.51
In recent studies we have demonstrated how complexes like
14+ and its analogues can be employed as optical probes for
STED, a powerful technique that can, potentially, produce
resolutions equal to those of stochastic techniques such as
STORM.65,67–69 In our 3D-STED experiments, the resolution of
images probing localization of 44+ on the membrane of SH1000
cells was improved up to 43 nm and we regularly resolved
structural patterns below 80 nm in the XY plane and above
150 nm in the axial plane – Fig. 5. The direct imaging of the cell
septum indicated that the compound is not bound to the
peptidoglycan within the cell wall; instead 44+ is localized
within or on the membrane. At the improved resolutions
provided by 3D-STED the uneven accumulation observed using
SIM is revealed to be a distinctive patterning over the entire
surface of the S. aureus membrane.
Fig. 3 Accumulation experiments. ICP-AES data for the uptake of
ruthenium by S. aureus, SH1000, after exposure to 44+ in the absence
(AI) and presence (AII) of glucose. Ru (blue) and Fe (red) levels per cell
are exposed as metal (g) per cell. T-test stats are given as a comparison
at each time-point (B). Fe levels were calculated as a control. Condi-
tions: concentration of 44+ ¼ 4 mM. Cells were washed with 0.5% (v/v)
nitric acid to remove unbound complex. Error bars represent three
independent biological repeats SD.
Fig. 4 Super-resolution SIM imaging revealing localization of 44+ in S.
aureus SH1000 cells at (A) 5 min and (B) 60 min. Cells images using the
emission of 44+ on excitation at 450 nm using the A568 ﬁlter. After
treatment with 4 mM 44+, cells were washedwith PBS before ﬁxing with
paraformaldehyde (4%).
Fig. 5 Stimulated emission depletion (STED) nanoscopy. Represen-
tative data showing section planes of full-volume cells deconvoluted
diﬀraction-limited (d-LCSM, green) and 3D super-resolution images
(Red, d-3D STED). Zoomed in areas of the white square are shown in
adjacent images, as well as the orthogonal representation of every axis
(XY, XZ and YZ), where the increased resolution and better localization
of 44+ is shown in red. This reveals accumulation at speciﬁc locations
within the cell membrane. Conditions: after 60 minute treatment with
4 mM 44+, cells were washed with PBS before ﬁxing with para-
formaldehyde (4%).
Chem. Sci. This journal is © The Royal Society of Chemistry 2019
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As complexes 14+–54+ are all known to bind nucleic acids45,51
and the parent compound localizes in the nucleus of eukaryotic
cells,46 the commonly used prokaryotic and eukaryotic DNA
stain DAPI was also used as a co-stain to determine whether
DNA is targeted once 44+ internalizes with cells imaged using
SIM – Fig. 6.
Visual inspection of images recorded aer 10 minutes of
exposure indicated that the intracellular accumulation of 44+
and DAPI do not strongly overlap, which is conrmed by
a relatively low Pearson's correlation coeﬃcient of 0.28. At 60
minutes there is an increase in co-localization with the Pearson
coeﬃcient rising to 0.49. As these data suggest that the complex
binds to DNA within SH1000 cells this could result in increased
mutational rates. Therefore, a mutagenesis assay (Ames test –
uctuation method) was performed; see ESI.†
These tests reveal that, at concentrations above the MIC,
exposure to 44+ results in bacterial DNA damage, providing
further evidence that the complex does bind intracellular DNA.
However, this eﬀect is less pronounced than that caused by
exposure to mutagenic UV-irradiation, suggesting that, above
the MIC concentration, DNA damage is only a contributing
cause of cell death and is part of a multi-target mechanism of
action.
Further co-staining studies with a second imaging probe –
the commonly used membrane and cell wall stain NHS-ester
405 – resulted in some revealing results – see ESI.† Initially,
co-localization tests between NHS-ester and 44+ show a high
correlation; however, co-localization decreases over 60 minutes
when there is a concomitant increase in DAPI co-localization.
These data suggest that 44+ initially binds to bacterial cell
surface regions, then consequently internalizes and increas-
ingly binds to DNA.
Revealingly, when the NHS-ester is added to cells aer 44+,
within 20 minutes NHS-ester staining around the periphery of
cells becomes discontinuous. Aer 60 minutes of exposure this
discontinuity becomes increasingly prominent – see ESI,† con-
rming the induction of cell damage.
Many of the observations described above are consistent
with our previous research on Gram-negative bacteria, which
showed that cell membrane damage occurs on exposure to 44+.
To conrm an analogous mechanism operates in Gram-positive
bacteria, the integrity of the S. aureus membranes on treatment
with 44+ was tested through an ATP release assay. In this assay,
cells were exposed to 44+ at its MIC and 0.5 MIC – see ESI.†
These experiments showed that treated cells release more ATP
than untreated controls. Furthermore, at the MIC concentration
a build-up of cellular debris was observed, indicating that cell
lysis was occurring.
The eﬀect of 44+ on the membrane potential of S. aureus cells
was also measured using the membrane potential dye DiOC2(3)
– Fig. 7. In intact bacteria cells DiOC2(3) emits in the green;
however once a membrane is polarized and its potential
Fig. 6 DAPI co-localization SIM experiments. Cells imaged using the
emission of 44+ on excitation at 450 nm using the 488 nm laser and
the A568 ﬁlter (A), emission of DAPI using the 405 nm laser and DAPI
ﬁlter (B), overlay image (C). After treatment with 4 mM 44+, cells were
incubated with DAPI for 5 minutes and washed with PBS before ﬁxing
with paraformaldehyde (4%).
Fig. 7 Detection of membrane potential in S. aureus SH100 cells. Red/
green cell populations were calculated using population mean ﬂuo-
rescence intensities for S. aureus cells incubated with 30 mM DiOC2(3)
for 30minutes, in the presence or absence of mMof 44+ for 10minutes.
Top: Percentage population is shown in two representation styles.
Analysis was conducted using red and green ﬂuorescence parameters.
Bottom: The red-versus green ﬂuorescence dot plots. Flow cytometer
data were collected with log ampliﬁcation.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci.
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increases the emission of DiOC2(3) undergoes a red shi, due to
dye self-association at higher cytosolic concentrations.70 A
diagnostic shi from green to red (red-green) is observed when
cells are treated with 44+ at its MIC concentration, signifying an
increase in membrane potential. Together, these two experi-
ments provide denitive proof that exposure to 44+ does lead to
membrane damage in S. aureus.71,72
As 44+ contains two electron dense RuII-centres, it is an
excellent contrast stain for Transmission Electron Microscopy
(TEM). Therefore, damage to the cell wall and membrane was
directly imaged using TEM – Fig. 8.
From these images it is clear the compound causes disrup-
tion to both the cell wall and the cell membrane within 20
minutes. At concentrations above its MIC, complex 44+ causes
rapid cell death; cell walls appear swollen, and blebbing/
channelling is evident. These eﬀects account for the ATP
leakage and membrane potential changes seen in the
membrane damage assays.
As complex 44+ displays high activity against a wild-type
strain and appeared to function through multi-target mecha-
nisms that are analogous to those observed in Gram-negative
pathogens, its activity against other S. aureus strains was then
investigated. This screen involved a clinical isolate strain taken
from a patient with septic arthritis and septicaemia and
a conrmed MRSA strain BH1CC – Table 3. BH1CC is a mecA
positive, methicillin resistant strain of S. aureus.
In contrast to our work on pathogenic drug resistant Gram-
negative bacteria, a signicant decrease in activity is observed
across both strains in comparison to SH1000. This suggests
some strain specic susceptibility against 44+. The molecular
basis for resistance was therefore investigated.
Although the cellular responses of S. aureus are similar to
those observed for E. coli, one noticeable diﬀerence is the
distinctive punctated, cell-associated pattern of 44+ – in S.
aureus cell walls, shown in Fig. 4 and 5. This suggests that the
initial interaction of the complex with Gram-positive and Gram-
negative bacteria is diﬀerent. This is not surprising – a major
diﬀerence between these two classes of microorganisms is the
composition and structure of their cell walls. To investigate this
issue, a series of more specialized experiments were carried out.
One obvious diﬀerence between the two classes is that the
cell wall of Gram-positive bacteria contains a much thicker
outer peptidoglycan layer compared to Gram-negative bacteria.
Indeed, the biosynthesis of this structure is the established
therapeutic target of both beta-lactam and glycopeptide anti-
biotics.73 To ascertain whether this component of the cell wall is
a binding target for 44+, co-staining with a blue emitting
peptidoglycan stain – the D-amino acid, HCC-amino-D-alanine
(HADA) – was carried out and imaged through SIM, Fig. 9.74
These experiments revealed that, although some co-localization
between the two dyes emerged aer 60 minutes exposure, the
initial distinctive distribution of 44+ shows little co-localization
with HADA; therefore, specic peptidoglycan binding by the
complex can be discounted.
A second characteristic feature of cell walls in Gram-positive
bacteria is that it is densely functionalized with glycopolymers.
The two most common glycopolymers, wall teichoic acid and
lipoteichoic acid, contain anionic residues and also moieties
that protrude from the cell wall.75–78 As these structures are
known to bind extracellular metal cations, the possibility that
they interact with 44+ was then investigated.
To address this question, experiments on two mutant strains
of S. aureus were carried out. The tarO strain is decient in wall
teichoic acids,79 whilst the dltA strain is specically decient in
D-alanylated teichoic acids.80
First, MICs for these two mutants were quantied and
compared to the data obtained for the SH1000 wild-type strain –
Table 4. These data revealed that both mutant strains possess
lower MICs for 44+ than SH1000, indicating that binding to the
anionic residues of teichoic acid in the wild-type strain lowers
susceptibility to 44+ and prevents the compound from reaching
other cellular targets. This hypothesis is consistent with
previous studies showing increased synthesis of wall teichoic
acid is a known resistance mechanism in S. aureus.
Imaging experiments involving the dltA mutant were also
revealing. Using SIM, the uptake and subsequent localization
Fig. 8 Detection of membrane damage using transmission electron
microscopy (TEM). Images were taken at (A) in the absence of
compound and at 20 (B), 60 (C) and 120 (D) minutes after exposure to
44+. In the healthy control the cell wall (CW), plasma membrane (PM)
and septum (S) are labelled. Cells were ﬁxed using 2.5% glutaraldehyde
in sodium cacodylate buﬀer (pH 7.4) and stained solely with 44+ (40
mM). The 0 minute control was stained with osmium tetroxide, uranyl
acetate and lead citrate.
Table 3 Comparative MIC (mM) results for SH1000, MRSA and an AMR
clinical isolate treated with complex 44+, in CDM and MH-II
Strain MH-II CDM
SH1000 40 4
BH1CC 76.5 38.3
Clinical isolate 51.0 19.1
Chem. Sci. This journal is © The Royal Society of Chemistry 2019
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pattern produced on exposure to 44+ were compared to SH1000,
Fig. 10. In contrast to the wild-type, staining of the dltA mutant
did not produce a punctated accumulation pattern over the
membrane and the septa of dividing cells are not signicantly
stained by 44+. Furthermore, although the mutant was exposed
to the same concentration of 44+ as the wild-type strain, dltA
displays brighter luminescence from the internalized complex,
suggesting a higher concentration of compound enters the cell.
This provides further evidence that binding to teichoic acids
within the cell wall of Gram-positive bacteria inhibits cellular
internalization and lowers the therapeutic potency of 44+.
The uptake of 44+ by dltA was monitored by measuring Ru
content (g) per cell using ICP-AES – see ESI† – Fe content was
also recorded. The experiment was conducted in the absence of
glucose to monitor the diﬀerences in compound uptake
between dltA and SH1000. The diﬀerent proles suggest
a diﬀerent mechanism of uptake. The intracellular concentra-
tion of 44+ at the earlier time-points (5, 10 and 20 min) is higher
in the dltA; however, the nal intracellular compound concen-
tration is similar across both strains. This supports the
hypothesis that 44+ binds teichoic acids on the cell membrane
preventing optimal intracellular concentrations, thus lowering
the activity. In addition, this observation is consistent with the
time-kill assays where signicant cell death occurs within the
rst 30 minutes of exposure to 44+, showing that the higher
initial intracellular concentration accounts for the lower MIC in
dltA cells. Cell viability was monitored through the course of the
experiment by CFU mL1 counts and the cells did not lyse.
Along with our previous work on Gram-negative bacteria, the
experiments described above demonstrate that exposure of S.
aureus cells to 44+ causes cell membrane damage and lysis. To
conrm this hypothesis and explore another known resistance
mechanism available to S. aureus we carried out experiments
with a third mutant strain, associated with membrane charge.
An established resistance mechanism to membrane active
agents in S. aureus involves up-regulation of mprF.80 This gene
codes for an enzyme that links lysine to negatively charged
phosphatidylglycerol and translocates the resulting positively
charged lysyl-phosphatidylglycerol to the outer leaet of the
cytoplasmic membrane, a process that increases positive charge
on the outer surface of the S. aureus membrane and thus
reduces susceptibility to cationic antibiotics. Knockout of mprF
necessitates that the bacterial membrane outer leaet retains
a higher negative charge compared to the wild-type.81,82
Revealingly, 44+ is considerably more active against this strain
than any other tested – Table 4.
Another known mechanism of resistance in MRSA strains is
upregulation of teichoic and lipoteichoic acids.83 To investigate
whether this may cause the decrease in activity of 44+ any
binding interactions were probed by STED nanoscopy – Fig. 11.
It is clear that in the MRSA strain, 44+ does not penetrate the cell
wall and membrane. Indeed, the complex is clearly retained on
the cell–wall and the previously described spotting
Fig. 9 Localization of 44+ and HADA in S. aureus SH1000 cells visu-
alized through SIM at 10, 20 and 60minutes. The emission of 44+ upon
excitation with the 488 nm laser was collected using the A568 ﬁlter (A),
emission of HADA from excitation with the 405 nm laser was collected
using the DAPI ﬁlter (B), overlay image (C). Cells were stained with
HADA for 5minutes prior to incubationwith 44+. After treatment with 4
mM 44+ cells were washed with PBS and ﬁxed with PFA (4%). Co-
localisation scatter plots are shown (D). See ESI† for Pearson's corre-
lation coeﬃcient.
Table 4 Comparative MIC (mM) results for SH1000, tarO, dltA and
mprF treated with complex 44+ in MH-II
Strain MIC
SH1000 40
dltA 20
tarO 15
MprF 1.5
Fig. 10 Localization of 44+ in S. aureus dltA cells visualized through
SIM at 20 min (left) and 60 min (right). Cells imaged using the emission
of 44+ on excitation at 450 nm using the A568 ﬁlter. After treatment
with 4 mM 44+, cells were washed with PBS before ﬁxing with para-
formaldehyde (4%).
This journal is © The Royal Society of Chemistry 2019 Chem. Sci.
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accumulation is noticeably more prevalent. Strikingly in these
3D-STED images the septa of the cell are no longer visible
conrming that the complex is not internalized. This supports
the hypothesis that the compound is electrostatically binding
teichoic and lipoteichoic acids, preventing high concentrations
of 44+ within the cell, thus lowering the activity.
Conclusions
Taken together, the studies in this report conrm that two of
the therapeutic targets of 44+ in bacteria are their cell
membranes and DNA content. Furthermore, the experiments
on the mutant strains reveal that the reason the complex is
more active against Gram-negative bacteria compared to Gram-
positive bacteria is due to intrinsic diﬀerences in the molecular
structures of these microorganisms.
As discussed above, as has been observed with other anti-
bacterials accretion of cationic lysyl-phosphatidylglycerol resi-
dues on the outside of the cytoplasmic membrane inhibits
internalization of the complex. Indeed a very recent report on
helicates, published as we compiled this study, showed that
bacterial resistance to such systems also involves reduction of
net negative surface charge.84 Cell walls densely functionalized
with the glycopolymers teichoic acid and lipoteichoic acids also
provides an additional barrier to uptake toward 44+.
Identication of these mechanisms provide new therapeutic
opportunities. For example, studies have shown that combina-
tions such as a small molecule tarO inhibitor that blocks the
production of WTA and a conventional antimicrobial are
synthetically lethal to therapeutically resistant bacterial
strains.85,86 Such a strategy will be explored in future work.
Furthermore, the identication of resistance mechanisms in S.
aureus strains has aﬀorded insights into the on-going
construction of new molecular architectures, based on 44+,
possessing structural features designed to mitigate the eﬀect of
these mechanisms.
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